SCHEMBL8881971

SCHEMBL8881971

C=C(c1ccccc1)P(=O)(OC)OOC(C)CC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.38
POLB P06746 2/20 0.38
ALDH1A1 P00352 3/20 0.35
RAB9A P51151 2/20 0.35
MAPT P10636 5/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
XBP1 P17861 1/20 0.34
ATM Q13315 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
HPGD P15428 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
LAP3 P28838 1/20 0.33
KDM4E B2RXH2 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
PRSS1 P07477 1/20 0.32
CTSG P08311 1/20 0.32
CTRB1 P17538 1/20 0.32
CMA1 P23946 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8882633 0.83 TSHR (0.36) LMNAPOLBALDH1A1RAB9AMAPT
SCHEMBL9300378 0.78 LMNA (0.47) LMNAPOLBALDH1A1RAB9AMAPT
SCHEMBL7738533 0.71 NR1I2 (0.53) LMNAPOLBALDH1A1MAPTSMN1; SMN2
SCHEMBL11310450 0.70 LMNA (0.41) LMNAPOLBALDH1A1SMN1; SMN2KMT2A
SCHEMBL2322102 0.68 ALDH1A1 (0.41) LMNAPOLBALDH1A1RAB9AMAPT
SCHEMBL9300577 0.67 LMNA (0.46) LMNAPOLBALDH1A1RAB9AMAPT
SCHEMBL8467742 0.66 LMNA (0.55) LMNAPOLBALDH1A1MAPTTDP1
SCHEMBL20628180 0.65 MAPT (0.43) LMNAPOLBALDH1A1RAB9AMAPT
SCHEMBL8680382 0.64 LMNA (0.52) LMNAPOLBALDH1A1MAPTTDP1
SCHEMBL28475093 0.64 MAPT (0.46) LMNAPOLBALDH1A1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8557888-B2 Polymerizable compositions with improved through-curing depth IVOCLAR VIVADENT AG (LI) 2013-10-15 US disclosed
US-8557888-B2 Polymerizable compositions with improved through-curing depth IVOCLAR VIVADENT AG (LI) 2013-10-15 US disclosed
US-20120302657-A1 Polymerizable compositions with improved through-curing depth IVOCLAR VIVADENT AG (LI) 2012-11-29 US disclosed
US-20120302657-A1 Polymerizable compositions with improved through-curing depth IVOCLAR VIVADENT AG (LI) 2012-11-29 US disclosed
EP-2455059-A1 Polymerisable compound having improved hardening depth Ivoclar Vivadent AG (LI) 2012-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302657-A1 Polymerizable compositions with improved through-curing depth NR4A2, NR2C2, NOS2 LMNA 634/4885POLB 794/4885ALDH1A1 3730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.